FDA approved lutetium Lu 177 dotatate for the treatment of somatostatin receptor-positive GEP-NETs

/0 Comments/in , /by

 

  • FDA approved lutetium Lu 177 dotatate (LUTATHERA, Advanced Accelerator Applications USA, Inc.) a radiolabeled somatostatin analogue, for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumours in adults. More Information.
You might also like
Nivolumab approved for sorafenib-refractory HCC
Keytruda® FDA approved for recurrent and metastatic Merkel cell carcinoma
Moxetumomab pasudotox-tdfk FDA approved for hairy cell leukaemia
Cabozantinib FDA approved in HCC patients failing sorafenib
Trastuzumab/hyaluronidase-oysk subcutaneous formulation FDA approved for HER2‑overexpressing breast cancer
FDA approved durvalumab as maintenace for unresectable stage III NSCLC responding to platinum-based chemoradiation therapy
Glasdegib plus low-dose cytarabine (LDAC) approved in elderly AML patients
Enzalutamide FDA approved for castration-resistant prostate cancer (CRPC)
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *

FDA granted regular approval to olaparib in the treatment of (suspected) deleterious...FDA approved abiraterone acetate tablets plus prednisone for metastatic high-risk...